The Bet Behind Davide Campari Milano's Rally

If you only skimmed the Davide Campari-Milano headlines, the Q1 2026 update looked simple enough. Organic sales grew 2.9% and management stuck with roughly 3% guidance, even as new US import tariffs added a €30 million headache and North American net sales took a hit from inventory pruning on non-priority labels. Investors who held Davide Campari-Milano from the start of the year are up 21.8%, including dividends. If you were deciding back on 2026-01-01, what belief about that mix of global expansion hopes and tariff, volume and pricing risks would have felt strong enough to justify investing in the stock?

The easy part of this move is behind Davide Campari-Milano. Zero in on 196 high quality undervalued stocks for companies trading below our estimates.

The Argument You Would Have Been Weighing On Davide Campari-Milano

The shares cost €5.53 at the start of the period, and anyone looking at Davide Campari-Milano then had to choose which story felt more convincing.

The optimistic narrative tied a Fair Value of €6.75, a price implied by its own assumptions, to a thesis that global expansion across the US, APAC and EMEA alongside portfolio streamlining and capacity investment could support higher margins.

The more cautious script anchored on a Fair Value of €4.2 and focused on long term declines in alcohol consumption together with rising compliance and input costs as threats to demand, pricing power and profitability.

What The Results Changed For Davide Campari-Milano

The Q1 2026 update from Davide Campari-Milano kept around 3% organic growth guidance in place and flagged a €30 million tariff hit, which leaned toward the cautious script on rising costs. Reported H1 2026 figures then showed revenue at €1,512 million and net income at €129 million, with net margin falling from 13.5% to 8.5%. The evidence cut both ways.

The hinge assumption here was margin resilience under cost and regulatory pressure. For a different stock with a similar story, it can be useful to focus on whether earnings and net margin move in the same direction as promised efficiency gains or pricing power, rather than only tracking sales.

What Today's Davide Campari-Milano Price Already Assumes

Davide Campari-Milano trades at €6.61 after a 21.8% gain from the start of the year. The selected Narrative’s Fair Value sits below the current price and frames that gap around mix quality, cost pressure and exposure to developing markets rather than simple top line momentum.

To pay today’s price, you would be assuming that margin and free cash flow benefits from efficiency programs and portfolio changes will outweigh rising logistics, insurance and tariff costs over time.

"The long-term thesis still depends on Campari successfully turning cost efficiency programs, portfolio streamlining and capacity investments into sustained margin and free cash flow strength, while external headwinds such as tariffs and geopolitics persist. The current valuation implies the share price already reflects continued organic growth, margin accretion and developing-market expansion, which leaves limited room for disappointment if category, tariff or cost risks affect earnings."

That disagreement has a full argument behind it. → Uncover the lower Fair Value this Narrative argues for

Before The Next Story Makes Headlines

You may be late to this rally, but that does not have to mean arriving late to every opportunity. Start with companies whose prices leave room for a different view of their future. Here are three trading below our estimates.

• Company 1 - 46% below our estimate - captures hyperscaler AI hardware ramps shifting into higher margin programs and services.
• Company 2 - 32% below our estimate - rides demand for GPU racks that pressure power capacity at fast expanding data centres.
• Company 3 - 42% below our estimate - converts complex AI, utility and chemicals regulation into recurring specialised consulting engagements.

That is three of the list. See all 203 companies with the balance sheet to back it up →

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com